Novel immunotherapies for life-threatening inflammatory syndromes

Inotrem is developing novel immunomodulators that target the TREM-1 pathway. The company’s lead compound, nangibotide, is a first-in-class anti-TREM-1 peptide and is currently in phase 2 trials for septic shock.

Like Comment
Page of
Go to the profile of Inotrem

Inotrem

Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock. Founded in 2013, with offices in Paris and a technology center in Nancy (France), the company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide (LR12), with applications in a number of therapeutic indications such as septic shock or myocardial infarction. Next to acute inflammatory syndromes, Inotrem is also developing a program targeting chronic inflammatory diseases

No comments yet.